Daniel Soffer: ApoA-1 vs HDL-C as Markers of Cardiovascular Risk
Pablo Corral Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Selin Bilgic et al., published in Journal of Clinical Lipidology, adding:
“ApoA-1 versus HDL-C as markers of cardiovascular risk
HDL-C or ApoA-1:which better reflects cardiovascular risk?
A new analysis from nearly 300,000 UK Biobank participants revisits one of the oldest debates in lipidology:
Key findings:
- ApoA-1 and HDL-C showed similarly strong inverse associations with ASCVD risk
- ApoA-1 explained most of the protective signal traditionally attributed to HDL-C
- Triglycerides contributed far less than expected
- HDL biology may still matter more than many currently assume
Interesting message from this paper:
The story of HDL is probably more nuanced than simply saying ‘HDL is not causal.’
Negative HDL-raising trials did not kill the biology.
They only killed simplistic pharmacology.”
Daniel soffer, Associate Professor of Medicine at University of Pennsylvania, shared this post on LinkedIn:
“Pablo Corral, as usual your posts and commentary are brilliant.
Clearly, HDL is important and clearly, we are measuring what it does poorly.
Manipulating its cholesterol content in serum and even how many HDL particles are in circulation is not the secret.
Perhaps we will figure out how to manipulate HDL for good one day beyond eating healthy, exercising regularly, managing sleep and stress.”
Title: ApoA-1 versus HDL-C as markers of cardiovascular risk
Authors: Selin Bilgic, Karol Pencina, Michael Pencina, Line Dufresne, George Thanassoulis, Allan Sniderman
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning
-
Oct 9, 2026, 14:07Chokri Ben Lamine: Pain After Allogeneic Stem Cell Transplantation in Sickle Cell Disease
-
Oct 9, 2026, 13:55Chandler Purser: AABB 2026 Focuses on Transfusion Safety and Audit-Driven Practice Improvement